Dianiklin

Dianiklin
(IUPAC) ime
	(5aS,8S,10aR)-5a,6,9,10-Tetrahidro,7H,11H-8,10a-metanopirido[2',3':5,6]pirano[2,3-d]azepin
Klinički podaci
Identifikatori
CAS broj	292634-27-6
ATC kod	nije dodeljen
PubChem	9816447
UNII	Y0SNM34C6O
Hemijski podaci
Formula	C13H16N2O
Mol. masa	216,278
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C13H16N2O/c1-2-11-10(14-5-1)8-13-4-7-15(9-13)6-3-12(13)16-11/h1-2,5,12H,3-4,6-9H2 ; Key: SUPRUPHAEXPGPF-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Dianiklin (SSR-591,813) je lek koji je razvilo preduzeće Sanofi-Aventis. On deluje kao parcijalni agonist na neuronskim nikotinskim acetilholinskim receptorima. On je selektivan za podtip α4β2. Ovaj ligand je razvijen za primenu u tretmanu nikotinske zavisnosti kao pomoć u suzbijanju želje za pušenjem.^[3] Dianiklin je veoma sličan vareniklinom, koji se raznije pojavio na tržištu. Dianiklin ima manje izražene nuspojave. On je uspešno prošao kroz Fazu II kliničkih ispitivanja. Razvoj leka je prekinut zbog nepovoljnog ishoda kliničkih ispitivanja u Fazi III.^[4]^[5]^[6]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Leonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrie P, Scatton B. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. Journal of Pharmacology and Experimental Therapeutics. 2003 Jul;306(1):407-20. PMID 12682217
↑ Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs. 2006; 15(2):107-116.
↑ Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation
↑ „Sanofi Pipeline”. Arhivirano iz originala na datum 2008-12-04. Pristupljeno 2014-04-05.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Leonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrie P, Scatton B. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. Journal of Pharmacology and Experimental Therapeutics. 2003 Jul;306(1):407-20. PMID 12682217

[4] Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs. 2006; 15(2):107-116.

[5] Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation

[6] „Sanofi Pipeline”. Arhivirano iz originala na datum 2008-12-04. Pristupljeno 2014-04-05.

[1]

[2]

[3]

[4]

[5]

[6]